- 1995 was a very good year for Idec Pharmaceuticals, according to William Rastetter, president and chief executive. The firm received revenues from contract research and licensing fees of $23.6 million, up 46%. A net loss was reported in 1995 of $17.3 million or $1.18 per share, which were slight decreases on those in 1994. The 1995 results included a one-time, non-cash charge of $11.4 million for the purchase of technology.
For the fourth quarter of 1995, revenues were $10.7 million, up 234%. Net income in the quarter was $2.7 million or $0.14 per share, compared with a net loss a year earlier of $2.8 million and a loss per share of $0.23.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze